Marshall Wace LLP Takes Position in Altimmune, Inc. (NASDAQ:ALT)

Marshall Wace LLP bought a new position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 65,517 shares of the company's stock, valued at approximately $472,000. Marshall Wace LLP owned approximately 0.09% of Altimmune as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the company. Invesco Ltd. increased its position in Altimmune by 679.2% during the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after buying an additional 215,375 shares during the period. Wells Fargo & Company MN grew its position in shares of Altimmune by 69.3% during the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock worth $1,554,000 after acquiring an additional 88,209 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Altimmune by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company's stock valued at $1,482,000 after acquiring an additional 31,482 shares during the period. Wellington Management Group LLP raised its position in Altimmune by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 205,233 shares of the company's stock valued at $1,480,000 after purchasing an additional 8,001 shares during the last quarter. Finally, Barclays PLC boosted its stake in Altimmune by 1.1% during the 4th quarter. Barclays PLC now owns 157,528 shares of the company's stock worth $1,135,000 after purchasing an additional 1,787 shares during the period. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Price Performance

Shares of ALT stock traded up $0.06 during midday trading on Thursday, reaching $5.42. 579,433 shares of the company traded hands, compared to its average volume of 2,852,481. The firm has a market cap of $417.42 million, a PE ratio of -3.50 and a beta of 1.13. The firm's 50 day simple moving average is $5.10 and its two-hundred day simple moving average is $6.62. Altimmune, Inc. has a 1-year low of $3.55 and a 1-year high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. As a group, research analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ALT. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. William Blair reissued a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Altimmune currently has a consensus rating of "Buy" and a consensus price target of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.